Evaluation of rabies biologics against irkut virus isolated in China

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3499-3504

  Liu, Ye ^a   Chen, Qi ^a   Zhang, Fei ^a   Zhang, Shoufeng ^a   Li, Nan ^a   Lian, Hai ^a   Wang, Ying ^a   Zhang, Jinxia ^a   Hu, Rongliang ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RABIES IMMUNOGLOBULIN; RABIES VACCINE; RECOMBINANT ALPHA2A INTERFERON;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHINA; CONTROLLED STUDY; FEMALE; IRKUT VIRUS; IRKUT VIRUS INFECTION; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; RABIES VIRUS; RHABDOVIRUS INFECTION; SYRIAN HAMSTER; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ANIMALS; BIOLOGICAL PRODUCTS; CHINA; CRICETINAE; CROSS PROTECTION; DISEASE MODELS, ANIMAL; FEMALE; LYSSAVIRUS; MESOCRICETUS; POST-EXPOSURE PROPHYLAXIS; RABIES VACCINES; RHABDOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINATION;

EID: 84886512410     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01565-13     Document Type: Article

References (33)

1. Kuzmin IV, Tordo N.2012.Genus lyssavirus, p 37-57.In Dietzgen RD, Kuzmin IV (ed), Rhabdoviruses: molecular taxonomy, evolution, genomics, ecology, host-vector interactions, cytopathology and control.Caister Academic Press, London, United Kingdom.
2. Marston DA, Horton DL, Ngeleja C, Hampson K, McElhinney LM, Banyard AC, Haydon D, Cleaveland S, Rupprecht CE, Bigambo M, Fooks AR, Lembo T.2012.Ikoma lyssavirus, highly divergent novel lyssavirus in an African civet.Emerg. Infect. Dis.18:664-667.
3. Freuling CM, Beer M, Conraths CD, Finke S, Hoffmann B, Keller B, Kliemt J, Mettenleiter TC, Mühlbach E, Teifke JP, Wohlsein P, Müller T.2011.Novel lyssavirus in Natterer's bat, Germany.Emerg. Infect. Dis.17:1519-1522.
4. Arechiga Ceballos N, Vazquez Morón S, Berciano JM, Nicolás O, Aznar López C, Juste J, Rodriguez Nevado C, Aguilar Setién A, Echevarría JE.2013.Novel lyssavirus in bat, Spain.Emerg. Infect. Dis.19:793-795.
5. Hu RL, Tang Q, Tang JR, Fooks AR.2009.Rabies in China: an update.Vector Borne Zoonotic Dis.9:1-12.
6. Liu Y, Zhang SF, Zhao J, Zhang F, Hu RL.2013.Isolation of Irkut virus from a Murina leucogaster bat in China.PLoS Negl.Trop.Dis.7:e2097.doi:10.1371/ journal.pntd.0002097.
7. Leonova GN, Belikov SI, Kondratov IG, Krylova NV, Pavlenko EV, Romanova EV, Chentsova IV, Petukhova SA.2009.A fatal case of bat lyssavirus infection in Primorye Territory of the Russian Far East.Rabies Bull.Eur.33:5-8.
8. Badrane H, Bahloul C, Perrin P, Tordo N.2001.Evidence of two lyssavirus phylogroups with distinct pathogenicity and immunogenicity.J. Virol.75:3268-3276.
9. Hanlon CA, Kuzmin IV, Blanton JD, Weldon WC, Manangan JS, Rupprecht CE.2005.Efficacy of rabies biologics against new lyssaviruses from Eurasia.Virus Res.111:44-54.
10. Hall TA.1999.BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/95/NT.Nucleic Acids Symp.Ser.41:95-98.
11. Liu Y, Zhang SF, Zhang F, Hu RL.2012.Adaptation of a Chinese ferret badger strain of rabies virus to high-titered growth in BHK-21 cells for canine vaccine development.Arch.Virol.157:2397-2403.
12. Meslin F-X, Kaplan MM, Koprowski H (ed).1996.Laboratory techniques in rabies, 4th ed, p 80-168.World Health Organization, Geneva, Switzerland.
13. Ministry of Science and Technology (MOST) of the People's Republic of China.2006.Guideline on humane treatment of laboratory animals.Ministry of Science and Technology, Beijing, China.
14. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL.2000.A simple method for the rapid generation of recombinant adenovirus vectors.Gene Ther.7:1034-1038.
15. Cliquet F, Aubert M, Sagné L.1998.Development of a fluorescent antibody virus neutralization test (FAVN test) for the quantitation of rabies-neutralizing antibody.J.Immunol.Methods 212:79-87.
16. Aubert MFA.1996.Methods of the calculation of titers, p 445-456.In Meslin FX, Kaplan MM, Koprowski H (ed), Laboratory techniques in rabies, 4th ed.World Health Organization, Geneva, Switzerland.
17. Houimel M, Dellagi K.2009.Peptide mimotopes of rabies virus glycoprotein with immunogenic activity.Vaccine 27:4648-4655.
18. Bunschoten H, Gore M, Claassen IJ, Uytdehaag FG, Dietzschold B, Wunner WH, Osterhaus AD.1989.Characterization of a new virusneutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein.J.Gen.Virol. 70:291-298.
19. Benmansour A, Leblois H, Coulon P, Tuffereau C, Gaudin Y, Flamand A, Lafay F.1991.Antigenicity of rabies virus glycoprotein.J. Virol.65: 4198-4203.
20. Torvaldsen S, Watson T.1998.Rabies prophylaxis in Western Australia: the impact of Australian bat lyssavirus.Commun.Dis.Intell.22:149-152.
21. Horton DL, McElhinney LM, Marston DA, Wood JL, Russell CA, Lewis N, Kuzmin IV, Fouchier RA, Osterhaus AD, Fooks AR, Smith DJ.2010.Quantifying antigenic relationships among the lyssaviruses.J. Virol.84: 11841-11848.
22. World Health Organization.2002.Monoclonal antibody cocktail for rabies post exposure treatment: report of aWHOconsultation, 23-24 May 2002.WHO document R2-370-15.World Health Organization, Geneva, Switzerland.
23. Both L, van Dolleweerd C, Wright E, Banyard AC, Bulmer-Thomas B, Selden D, Altmann F, Fooks AR, Ma JK.2013.Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans.FASEB J.27: 2055-2065.
24. Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-van der Horst M, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, de Kruif J, Rupprecht CE, Dietzschold B, Goudsmit J, Bakker AB.2005.Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis.J. Virol.79:4672-4678.
25. Müller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, Fehlner-Gardiner C, Kliemt J, Meslin FX, Franka R, Rupprecht CE, Tordo N, Wanderler AI, Kieny MP.2009.Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.PLoS Negl.Trop.Dis.3:e542.doi:10. 1371/journal.pntd.0000542.
26. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgoda M, Hanlon CA, Thijsse S, Backus HH, de Kruif J, Dietzschold B, Rupprecht CE, Goudsmit J.2005.Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.J. Virol.79:9062-9068.
27. Wang Y, Rowley KJ, Booth BJ, Sloan SE, Ambrosino DM, Babcock GJ.2011.Gglycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates.Antiviral Res.91:187-194.
28. Sloan SE, Hanlon C, Weldon W, Niezgoda M, Blanton J, Self J, Rowley KJ, Mandell RB, Babcock GJ, Thomas WD, Jr, Rupprecht CE, Ambrosino DM.2007.Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates.Vaccine 25:2800-2810.
29. Wilde H, Sirikawin S, Sabcharoen A, Kingnate D, Tantawichien T, Harischandra PA, Chaiyabutr N, de Silva DG, Fernando L, Liyanage JB, Sitprija V.1996.Failure of postexposure treatment of rabies in children.Clin. Infect. Dis.22:228-232.
30. Hilfenhaus J, Weinmann E, Majer M, Barth R, Jaeger O.1977.Administration of human interferon to rabies virus-infected monkeys after exposure.J. Infect. Dis.135:846-849.
31. Vos A, Neubert A, Pommerening E, Müller T, Döhner L, Neubert L, Hughes K.2001.Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration.J.Gen.Virol.82:2191-2197.
32. Bahloul C, Jacob Y, Tordo N, Perrin P.1998.DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses.Vaccine 16:417-425.
33. Jallet C, Jacob Y, Bahloul C, Drings A, Desmezieres E, Tordo N, Perrin P.1999.Chimeric lyssavirus glycoprotein genes with increased immunological potential.J. Virol.73:225-233.